Introduction
Celiac disease (CD) is a major health care issue worldwide, with a prevalence of about 1%, affecting people of all ages. 1 A permanent state of intolerance to gluten-containing food leads to chronic inflammation of the small intestine. Hallmarks of CD are lymphocytic infiltration of the lamina propria, expansion of the intraepithelial lymphocyte (IEL) population, hyperplasia of the crypts and atrophy of the villi. CD occurs in genetically susceptible individuals who almost always carry the HLA-DQ 2/8 alleles. 2, 3 Although improvement is usually seen upon life-long withdrawal of dietary gluten, a small percentage (2-5%) of the adult-onset CD patients, especially those diagnosed above the age of 50 years, lack clinical and histological response despite strict adherence to such a gluten-free diet for more than 12 months. Patients are classified as having refractory celiac disease (RCD) if dietary consumption of gluten and other causes of malabsorption with villous atrophy are ruled out. 4, 5 On the basis of immunophenotyping of the IEL, we can subdivide RCD into two groups: type I with phenotypically normal and type II with phenotypically aberrant IEL, aberrance being defined as lack of the surface markers CD3, CD4 and CD8, but with expression of cytoplasmic CD3. Clonal expansion of these aberrant IEL is thought to be responsible for progression to enteropathy-associated T-cell lymphoma (EATL). 4, 6, 7 The genesis and expansion of these monoclonal T cells involve both inappropriate immune responses to gluten and acquisition of genetic abnormalities. RCD II is in most patients resistant to most studied therapies, including corticosteroids, budesonide, infliximab, CYA, IL-10 and azathioprine/prednisone 8 and has a high risk of progressing to EATL (60-80% within 5 years). 9, 10 This peripheral T-cell lymphoma has a very poor prognosis with a 2-year survival of only 15%, mainly because of failure to respond to chemotherapy. 9, 10 Therefore, it is of utmost importance to evaluate new treatment strategies for RCD II patients, and in particular for those unresponsive to conventional immunosuppressive drugs to improve the clinical course and prevent or delay development of EATL.
Until 2005 in our tertiary referral center for RCD, type II patients were initially treated with conventional immunosuppressive drugs, mainly azathioprine or prednisone or both, and cladribine was prescribed if they were clinically and histologically unresponsive. Cladribine is a synthetic purine nucleoside homologue with cytotoxic activity. Since 2005 a modified treatment strategy has been initiated with cladribine being drug of first choice, based on a study showing that azathioprine combined with prednisone is not effective in most RCD II patients. 11 For patients not responding, an alternative was sought. High-dose chemo/ radiotherapy followed by auto-SCT has been effective therapy for refractory disease not only in hematological malignancies, but also in severe autoimmune disease. [12] [13] [14] In autoimmune disease, auto-SCT is supposed to induce immunoablation with subsequent regeneration of naive T lymphocytes derived from reinfused hematpoietic progenitor cells. [13] [14] [15] Analysis of our first seven RCD II patients treated with auto-SCT showed this treatment approach is feasible and well tolerated in celiac patients. Survival at that time seemed promising, but follow-up was short. 16 This analysis evaluates the follow-up of 18 RCD II patients, including 7 patients of our pilot study, who were selected for auto-SCT as a consequence of unresponsiveness to conventional immunosuppressive and/or cladribine therapy. Fifteen patients were treated in Amsterdam, one each in Italy, Portugal and Germany.
Patients and methods
This study reports extended follow-up of the open-label prospective phase I study performed by Al-Toma et al. 16 with six new transplanted patients added, who were referred after inclusion of this study was finished. Between March 2004 and February 2010, 18 cladribine-unresponsive RCD II patients were evaluated for auto-SCT.
Inclusion and exclusion criteria
Patients aged o70 years and diagnosed with RCD II were included when they showed no response to one or two courses of cladribine, administered i.v. in a dose of 0.1 mg/ kg per day for 5 consecutive days. Response was defined as clinical (improvement of signs and symptoms of malabsorption and weight gain) and histological (Marsh criteria 0/I) and/or immunological (420% decrease of aberrant IEL) remission. The diagnosis of RCD II was based on persisting or recurring symptoms and small intestinal villous atrophy after a former good response despite strict adherence to a gluten-free diet for at least 1 year. 5, 17 Furthermore, the clinically validated cutoff value of 420% aberrant IEL detected by flow cytometric analysis was used to distinguish RCD type I and type II. 7 A lower percentage of aberrant T cells was allowed in the presence of ulcerative jejunitis. T-cell receptor (TCR)-g gene rearrangement was performed as previously described. 7 Although this clonal TCR-g rearrangement is still a widely accepted additional method to define RCD II, Verbeek et al. 7 showed that the percentage of aberrant IEL detected by flow cytometric analysis is more accurate to define RCD II. EATL was excluded by several investigations after computed tomography (CT), 18 whole-body positron emission tomography, 19 magnetic resonance imaging enteroclysis, 20 upper gastrointestinal endoscopy, video capsule endoscopy 21 and/ or double-balloon enteroscopy. 22 This diagnosis was confirmed according to the World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues.
23 WHO performance status 24 had to be p2, and no severe concomitant cardiac, pulmonary, renal or hepatic disease was to be present. Active uncontrolled infection and HIV positivity were also exclusion criteria. ). All patients received standard antibacterial and antifungal prophylaxis during neutropenia and trimethoprim-sulfamethoxazole glutenfree syrup 480-960 mg daily until 6 months after transplantation. Total parenteral nutrition and blood and platelet transfusions were given if indicated.
Follow-up and criteria of response Before, during and after auto-SCT, a clinical assessment was carried out noting in particular signs and symptoms of malabsorption. Body mass index (BMI), WHO performance status, and the need for transfusions, for additional nutritional support and for additional antimicrobial treatment, were documented. Clinical remission is defined as improvement of diarrhea and constant or improved WHO performance status, combined with at least two of the following clinical parameters within the normal range or an improvement of X1 point: (1) BMI; (2) albumin and (3) Hb. Multiple duodenal biopsies were taken by upper gastrointestinal endoscopy to detect histopathological abnormalities and to perform IEL immunophenotyping by flow cytometry analysis 7, 25, 26 at different time points (3, 12 and 24 months) after auto-SCT. Isolation of small intestinal IEL and staining for immunophenotyping were performed as previously described. 7 Complete histological remission is defined as a normalization of the architecture of the small intestinal mucosa, classified as Marsh 0 or I lesion according to the modified Marsh criteria. 27 A decline of 420% in the percentage of aberrant IEL was considered a significant immunological remission. In addition, OS and the EATL occurrence were evaluated during follow-up.
Statistical analysis
Quantitative data were expressed as medians. KaplanMeier survival curves were constructed using SPSS software (SPSS Inc., Chicago, IL, USA).
Ethics approval and informed consent
Approval of the medical ethics committee was obtained, and all treated patients signed an informed consent in accordance with the Declaration of Helsinki Principles.
Results
In total, 18 RCD II patients (Table 1) who were refractory to cladribine therapy were eligible for auto-SCT. The median time between cladribine treatment and auto-SCT was 6.25 months. All patients entered the treatment protocol, however five patients did not make it to auto-SCT (Table 2 ) : two due to unsuccessful leukapheresis and in three patients progression into EATL occurred before stem cells could be collected, as depicted in Figure 2 . The patients reaching actual transplant (n ¼ 13) had a median follow-up time of 42 years, ranging from 10 to 67 months.
Survival and disease status
Out of the 18 patients unresponsive to cladribine, 8 patients died (44%), 5 of them due to EATL (28%). If auto-SCT was not reached for any reason, mortality in the nontransplanted cohort was high; all patients died within a median follow-up of 5.5 months (range 1-12.5 months). In the transplanted group, however, 23% (3 of 13) patients died. There was one transplant-related death due to septicemia with subsequent meningitis. The other two patients died of chronic encephalitis and EATL, complications associated with CD rather than transplantation. Interestingly, in the latter patient EATL occurred 4 years after transplantation (Figure 2) . All the five patients in whom EATL occurred died, with a mean survival of 2 months (range 0-8 months) after diagnosis. The overall 3-and 4-year survival after undergoing auto-SCT in case of unresponsiveness to cladribine therapy was 80 and 66%, respectively (Figure 3) .
Overall clinical, histological and immunological outcome is depicted in Table 3 . All transplanted patients reached follow-up of almost 1 year to assess remission status. Within 1 year after auto-SCT, the majority of patients (11 of 13) showed impressive clinical improvement with normalization of stool frequency, disappearance of gastrointestinal symptoms and normal levels of or improvement of X1 point in BMI, albumin and/or Hb. All patients had a WHO performance status of 0 at the end of follow-up. In addition, improvement of BMI was documented from a median level of 20.1 kg/m 2 at baseline to 22.5 kg/m 2 after auto-SCT. The median serum albumin level increased from 36 to 42 g/L (Table 3) . In total, 38% (5 of 13) had a complete histological remission, defined as Marsh 0 or I. Two of them achieved this remission within 3 months, two within 6 months and one after 2 years. One patient had a PR from a Marsh IIIB to Marsh II lesion and two patients already had a Marsh 0 and I lesion before auto-SCT. The remaining two patients showed stable and progressive histological abnormalities after auto-SCT. The median percentage of immunophenotypically aberrant intestinal T lymphocytes was 45% before transplantation and 54% at the end of follow-up. Only one patient showed a decrease in the percentage of aberrant T lymphocytes to within the normal value. The patient showed a clinical and complete histological remission as well.
Discussion
Till now there is no standardized treatment strategy for RCD II. 8 The high risk of subsequent progression to EATL with dismal prognosis highlights the need for new treatment strategies. Although treatment with conventional immunosuppressive drugs, including azathioprine and prednisone, may lead to clinical remission in several RCD II patients, 11,28,29 most of them do not have complete histological improvement, do not have a beneficial survival due to progression into EATL 11, 30 and/or become steroid dependent. 28 Therefore, in our medical center cladribine rather than azathioprine is prescribed, showing similar clinical improvement, but with better histological response rates without any steroid dependency and need for long-term medication. 31 However, approximately half of the patients is still clinically and histologically unresponsive to this therapy. In our analysis this specific group of RCD II patients refractory to cladribine therapy was scheduled for treatment with high-dose chemotherapy followed by auto-SCT.
In agreement with our pilot study, 16 we report in this larger cohort of RCD II patients that the treatment approach we described is feasible and no serious transplant-related short-term adverse events were noted. Moreover, during extended follow-up no secondary malignancies and myelodysplastic disorders were observed. Treatmentrelated mortality was not increased compared to other indications for auto-SCT.
The 5-year survival reported for RCD II, irrespective of treatment is currently 44-58%. 9, 28, 29 In these series, patients were initially treated with different types of medication, mainly conventional immunosuppressive drugs. In our analysis however, only RCD II patients unresponsive to these treatment options were scheduled for auto-SCT, having a 4-year survival of 66% if they manage to proceed transplantation. This survival rate seems promising so far, as this specific group of unresponsive patients has a worse prognosis. In addition, this is supported by the high mortality of the five refractory patients who could not be transplanted.
Four patients were already diagnosed as having overt EATL before first leukapheresis attempt, reflecting the quick development of this condition. The EATL rate observed in the transplanted group (1 of 13) is much better than that reported in published RCD II series (60-80%), 32 however, in a small series. Even if we include the nontransplanted patients who developed EATL, the EATL rate is less than reported (30%). As one transplanted patient developed an overt EATL only after 4 years of follow-up, chemotherapy followed by auto-SCT might possibly delay the development of this type of lymphoma. Whether progression into EATL is prevented or delayed must be elucidated by more prolonged follow-up.
In addition, in two patients transplantation could not be performed because of failure of stem cell collection, most likely as a consequence of previous administration of cladribine therapy. Both cladribine and fludarabine are purine nucleoside analogues. Although fludarabine-containing regimens are well known for impairing stem cell mobilization, less is known about the influence of cladribine on mobilization efficacy. 33 However, it seems from our data that cladribine might indeed influence stem cell collection. A solution might be mobilization after single-dose CY together with G-CSF and/or implementing plerixafor. 34 This new approach should be evaluated in this patient group.
Our study results showed an impressive clinical improvement and enhanced quality of life in almost all patients after transplantation. Approximately half of the patients had a significant recovery of the architectural abnormalities of the small intestinal mucosa. It is intriguing that a high percentage of aberrant IEL persists after auto-SCT, particularly in view of the improved Marsh score. These aberrant T cells reside in the intraepithelial as well as the lamina propria layer. 35 Although this percentage is crucial in the diagnostic work-up for distinguishing RCD types I and II, 7 our data suggest that the percentage of aberrant IEL is not suitable for monitoring therapy and predicting prognosis, at least in this cohort and time of follow-up. In fact, the percentage of aberrant T cells is not the same as the overall depletion of T cells after auto-SCT. Whether the absolute aberrant T-cell load, which might be quantified by flow cytometry or by quantitative positron emission tomography scanning, instead of the percentage of aberrant T cells is more suitable to predict prognosis is not clear yet.
If histopathology or another undefined parameter should be used to quantify mass needs to be investigated as well. Furthermore, clonal expansion of these aberrant IEL is considered to be responsible for progression into an EATL, however in our series the persisting high percentage of aberrant IEL after auto-SCT was not reflected in increased EATL development. In addition, the TCR-g rearrangement performed after auto-SCT could not detect a clonal peak with current available technology (data not shown). So far, it is still generally accepted that aberrant T cells are the factor responsible in EATL development. Thus, further reduction of T cells or T-cell mass by intensifying conditioning pre-auto-SCT might improve outcome. This could be achieved by a higher dose of fludarabine/ cladribine combined with anti-CD52 (alemtuzumab), antithymocyte globulin or new specific anti-T-cell agents.
Randomized clinical trials comparing conservative follow-up to auto-SCT, if unresponsive to cladribine therapy, are not available so far. In the future, multicenter randomized trials or trials with historical control groups will be needed to explore these new treatment strategies.
In conclusion, high-dose chemotherapy followed by auto-SCT in an RCD II patients unresponsive to cladribine therapy is well tolerated and no clinically relevant longterm complications were found so far. Moreover, if the patients manage to proceed auto-SCT, an impressive clinical and histological improvement is obtained, and survival rates so far are promising probably because of less progression to EATL.
